Eli Lilly's acquisition of Vere Therapeutics promises to revolutionize cardiovascular care with innovative one-time gene ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

What if a heart attack and lifetime of statin drugs could be avoided with a one-time, two-hour infusion? Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term ...

Lilly will acquire Verve Therapeutics and a pipeline of one-time treatments for cardiovascular diseases in a deal worth up to US$1.3 billion.

Key Points Eli Lilly is a leader in the weight loss drug market, generating blockbuster revenue. Viking Therapeutics recently launched a phase 3 trial for its weight loss candidate -- and could ...

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to pharmaceutical companies Pfizer and Eli Lilly.